Drugs / Innocell
Innocell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06366490 | Feb → Nov 2026 expected | ovarian carcinoma | PhotonPharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Innocell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06366490 ↗ |
| Known as | Innocell Autologous Cellular Immunotherapy | “Innocell Autologous Cellular Immunotherapy cells will be administered with CpG 1018 adjuvant ID every 2 weeks x 3 doses” NCT06366490 ↗ |
| Known as | Innocell vaccine | “This is a Phase 1, open-label, single-center, pilot study of Innocell autologous cellular immunotherapy (i.e., Innocell vaccine) in patients with recurrent EOC.” NCT06366490 ↗ |
| Modality | Cell therapy | “Innocell autologous cellular immunotherapy (i.e., Innocell vaccine)” NCT06366490 ↗ |
| Route | Other | “via intradermal (ID) injection” NCT06366490 ↗ |